Role of Radiotherapy in Unresectable Pancreatic Carcinoma

수술 불가능한 췌장암 환자에서 방사선 치료의 역할

  • Shin Hyun Soo (Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine) ;
  • Seong Jinsil (Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine) ;
  • Oh Won Yong (Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine) ;
  • Kim Gwi Eon (Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine)
  • 신현수 (연세대학교 의과대학 치료방사선과학교실, 연세암센터) ;
  • 성진실 (연세대학교 의과대학 치료방사선과학교실, 연세암센터) ;
  • 오원용 (연세대학교 의과대학 치료방사선과학교실, 연세암센터) ;
  • 김귀언 (연세대학교 의과대학 치료방사선과학교실, 연세암센터)
  • Published : 1993.06.01

Abstract

From 1988 to 1991, nineteen patients with unresectable localized pancreatic carcinoma were treated with radiotherapy and/or hyperthermia or in combination with chemotherapy. Radiation dose of 4500-5000 cGy with or without additional 500-1000 cGy was administered over 5 to 6 weeks to the pancreatic tumor area using 10 MV linear accelerator. Five of 19 patients were given chemotherapy, either neoadjuvant or maintenance setting with FAM regimen (5-FU, adriamycin and mitomycin C), which was repeated every 4 weeks for one year or until progression. Symptomatic palliation was achieved in 17 among 19 patients ($89{\%}$) and objective response (complete or partial response in CT finding) was achieved in 5 among 11 patients ($45{\%}$). The median survival time was 9 months and one-year survival rate, $32{\%}$. Local-regional failure was documented in 10 among 13 patients ($77{\%}$) and distant failures were found in the liver (3 patients) and carcinomatosis (2 patients). Prognostic significance of various factors such as age, sex, performance status, tumor location, stage, etc. were assessed. Any factors did not have the prognostic significance in univariate analysis. Treatment was well tolerated in most of the patients with only mild to moderate toxicity.

Keywords